Cover Image
Market Research Report
Product code 
1069324

Novel Cardiovascular Drug Delivery Devices Market, Distribution by Type of Drug Eluted (Sirolimus, Paclitaxel, Everolimus, Zotarolimus and Others), Stent Material (Platinum Chromium, Cobalt Chromium, Stainless Steel and Others),

Published: | Roots Analysis | 315 Pages | Delivery time: 1-2 business days

Price

Back to Top
Novel Cardiovascular Drug Delivery Devices Market, Distribution by Type of Drug Eluted (Sirolimus, Paclitaxel, Everolimus, Zotarolimus and Others), Stent Material (Platinum Chromium, Cobalt Chromium, Stainless Steel and Others),
Published: April 12, 2022
Roots Analysis
Content info: 315 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

Title:
Novel Cardiovascular Drug Delivery Devices Market
Distribution by Type of Drug Eluted (Sirolimus, Paclitaxel, Everolimus, Zotarolimus and Others), Stent Material (Platinum Chromium, Cobalt Chromium, Stainless Steel and Others), and Key Geographical Regions (North America, Europe, Asia, Middle East and North Africa, Latin America, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035.

Example Insights:

Overview

Cardiovascular diseases (CVD) are reported to be one of the leading causes of deaths across the globe, surpassing conditions, such as cancer and respiratory disorders. According to the WHO, around one third of the annual global deaths (an estimated 18 million) can be attributed to cardiac disorders. Specifically, coronary artery disease (CAD) is the most common form of cardiovascular disorder; around 11 million deaths were linked to this indication in 2020. It is worth mentioning that, in 2020 (post the onset of the pandemic) , a more than 3% increase in the deaths related to heart diseases was reported. Further, according to the Centers for Disease Control and Prevention, the financial burden (in terms of annual medical costs and loss of productivity)associated with cardio vascular diseases is expected to be surpass USD 1,000 billion, in 2030. In order to prevent the critical effects of vessel narrowing and plaque buildup in arteries, various coronary interventional devices are being used; cardiovascular stents have emerged as one of the most preferred solutions to mitigate the aforementioned concerns. Traditionally, bare-metal stent (BMS) was used extensively to open the blocked passages and restore adequate blood flow to the heart. In recent years, a shift in preference has been observed towards the use of drug-eluting stent (DES), which are coated with a polymer carrying an antiproliferative drug. Such stents have been demonstrated to reduce / prevent in-stent restenosis (re-narrowing of the arteries previously opened using angioplasty) , which was a major complication associated with the use of bare-metal stents. Drug eluting stents are considered to be revolutionary in the interventional cardiology domain, as they enable improved revascularization rates and reduced risk of thrombosis.

Presently, over 90 cardiovascular drug eluting stents are being offered by around 40 players located across the globe. Majority of such devices employ the use of metals, such as platinum chromium and stainless steel. Further, the patents focused on cardiovascular drug eluting stents and associated technologies have been filed / granted at a CAGR of 13%, in the past two decades. In this context, it is important to note that, over the past few years, there have been significant innovations in cardiovascular therapeutics domain, in terms of development of advanced bioresorbable stents, drug combinations, polymer and nanomaterial coatings, to further increase the safety and efficacy of these treatment options. For instance, recently, an implantable biocompatible stent containing miniaturized ultrasonic transducers have been proposed by a group of researchers, which can be used for real-time monitoring of restenosis in the patients. Moreover, recent advancements related to the use of augmented reality and deep learning can enable the development of patient-specific stents, paving the way for personalized-treatment for patients suffering from cardiovascular disorders. Given the ongoing pace of innovation in this field, adoption of cutting-edge technologies by device developers, the ever-increasing incidence of heart diseases and the rise in demand for associated treatments, we believe that the cardiovascular drug eluting stent market is likely to evolve at a rapid pace, over the coming years.

Scope of the Report

The "Novel Cardiovascular Drug Delivery Devices Market, Distribution by Type of Drug Eluted (Sirolimus, Paclitaxel, Everolimus, Zotarolimus and Others), Stent Material (Platinum Chromium, Cobalt Chromium, Stainless Steel and Others) and Key Geographical Regions (North America, Europe, Asia, Middle East and North Africa, Latin America, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035" report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of cardiovascular drug eluting stents in the healthcare domain, till 2035. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this market space. Amongst other elements, the report includes:

  • A detailed overview of the current market landscape of the players engaged in developing / manufacturing cardiovascular drug eluting stents, including information on their respective year of establishment, company size (in terms of number of employees), number of products offered and location of headquarters. Further, it provides a detailed assessment of the overall landscape of over 90 cardiovascular drug eluting stents, based on several relevant parameters, such as type of eluted drug, type of stent material, post dilatation limit, stent length, stent diameter, nominal pressure, rated burst pressure and administered drug concentration.
  • An in-depth analysis, highlighting the contemporary market trends, using five schematic representations, including a heat map representation (based on type of drug eluted and administered drug concentration), a stacked bar chart representation (by the type of drug eluted and stent material), a tree map representation (based on maximum stent length and maximum stent diameter), a 4D bubble chart representation comparing the players engaged in cardiovascular drug eluting stents domain (based on several relevant parameters (such as year of establishment, company size, number of products offered and location of headquarters) ) and a grid representation (based on company size, number of products offered, maximum stent length, maximum stent diameter and location of headquarters).
  • An insightful company competitiveness analysis of cardiovascular drug eluting stent developers, taking into consideration various relevant parameters, such as year of experience and portfolio strength (in terms of number of products offered, stent material, maximum stent length, maximum stent diameter, maximum nominal pressure, maximum rated burst pressure, and lowest strut thickness) .
  • Elaborate profiles of various prominent players that are currently engaged in developing / manufacturing drug eluting stents employed for the treatment of cardiovascular disorders, featuring a brief overview of the company (including information on its year of establishment, number of employees, location of headquarters, key members of the executive team and cardiovascular drug delivery device portfolio) , recent developments and an informed future outlook.
  • An in-depth analysis of the various patents that have been filed / granted related to cardiovascular drug eluting stents, based on various parameters, such as patent type, publication year, geographical location, CPC symbol, emerging focus areas, type of applicant and leading industry / non-industry players (in terms of the size of intellectual property portfolio) . Further, it features a three-dimensional bubble analysis (based on patent citation count, publication year, extended geographical reach) , patent benchmarking analysis and a detailed patent valuation analysis.
  • An insightful case study focused on novel cardiovascular therapeutics (such as gene therapy, next generation complements, oral proteins and peptides, regulatory t-cell (tregs) therapies and subcutaneous biologics) and novel cardiovascular-based services / solutions (such as biopharmaceutical contract research offerings, digital therapeutics and precision medicine software) . It also features a list of developers, along with details on their year of establishment, company size and location of headquarters.
  • An elaborate analysis in order to estimate the current and future demand for cardiovascular drug eluting stents, based on several relevant parameters, such as type of drug eluted (sirolimus, paclitaxel, everolimus, zotarolimus and others) , type of stent material (platinum chromium, cobalt chromium, stainless steel and others) and key geographical regions (North America, Europe, Asia, Middle East and North Africa, Latin America, and Rest of the World) for the period 2022-2035. Kindly note that input parameters considered for this analysis include number of patients suffering from cardiovascular disorders that can be treated using cardiovascular drug eluting stents and average price of such stents across various geographies.

One of the key objectives of the report was to estimate the existing market size and future opportunities associated with cardiovascular drug eluting stents over the next decade. Based on several parameters, such as annual cases reported for cardiovascular disorders, percutaneous coronary interventions performed (in terms of number of patients) to treat such disorders, and average price for associated drug eluting stents across various geographical regions, we have provided an informed estimate on the evolution of the market for the period 2022-2035. The report also features the likely distribution of the current and forecasted opportunity related to cardiovascular drug eluting stents market across type of drug eluted (sirolimus, paclitaxel, everolimus, zotarolimus and others) , type of stent material (platinum chromium, cobalt chromium, stainless steel and others) and key geographical regions (North America, Europe, Asia, Middle East and North Africa, Latin America, and Rest of the World) . In order to account for future uncertainties and add robustness to our forecast model, we have provided three forecast scenarios, portraying the conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

The opinions and insights presented in the report were influenced by discussions held with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with several industry stakeholders.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered:

  • Who are the leading players offering cardiovascular drug eluting stents?
  • Which type of drug eluting stent is most commonly offered by developers engaged in this market space?
  • What is the relative competitiveness of different players engaged in the development / manufacturing of cardiovascular drug eluting stents?
  • How has the patent landscape in this domain evolved over the last two decades?
  • What is the present and likely future demand for cardiovascular drug eluting stents in the overall healthcare sector?
  • What are the anticipated future trends related to cardiovascular drug eluting stents market?
  • How is the current and future opportunity likely to be distributed across key market segments?

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of cardiovascular drug eluting stents market and its likely evolution in the short to mid and long term.

Chapter 3 is an introductory chapter that highlights important concepts related to cardiovascular drug eluting stents. It also features information on various types of cardiovascular drug delivery devices, key indications targeted by such devices and potential risks associated with their use. This chapter further features details about the recent advancements that have been made related to cardiovascular drug delivery devices.

Chapter 4 provides a detailed overview of the current market landscape of players engaged in the development of cardiovascular drug eluting stents, along with information on their year of establishment, company size, number of products offered and location of headquarters. Further, it highlights a detailed assessment of the overall market landscape of over 90 cardiovascular drug eluting stents, based on several relevant parameters, such as type of drug eluted (sirolimus, paclitaxel, everolimus, zotarolimus and others) , type of stent material (platinum chromium, cobalt chromium, nitinol, stainless steel and others) , post dilatation limit, stent length, stent diameter, nominal pressure, rated burst pressure and administered drug concentration.

Chapter 5 features an analysis, highlighting the contemporary market trends through five different schematic representations, including a heat map representation based on eluted drug and administered drug concentration, a stacked bar chart representation based on the type of drug eluted and stent material, a tree map representation based on maximum stent length and maximum stent diameter, a 4D bubble chart representation comparing the players engaged in cardiovascular drug eluting stents domain, based on several relevant parameters (such as year of establishment, company size, number of products offered and region) , and a grid representation based on company size, number of products offered, maximum stent length, maximum stent diameter and location of headquarters.

Chapter 6 presents an insightful competitiveness analysis of players involved in the production / development of cardiovascular drug eluting stents, based on several relevant parameters, such as years of experience, portfolio strength (in terms of number of products offered, stent material, maximum stent length, maximum stent diameter, maximum nominal pressure, maximum rated burst pressure, and lowest strut thickness)

Chapter 7 features elaborate profiles of various prominent players that are currently engaged in providing cardiovascular drug eluting stents. Each company profile features a brief overview of the company (including information on its year of establishment, number of employees, location of headquarters, key members of the executive team and cardiovascular drug delivery device portfolio) , recent developments and an informed future outlook.

Chapter 8 provides an insightful analysis on patent focused on cardiovascular drug eluting stents. The chapter provides an overview on the filed / granted patents related to cardiovascular drug eluting stents. For this analysis, we looked at the patents that have been published by various players, till February 2022. The analysis highlights key details and trends associated with these patents, including patent type, publication year, geographical location, assigned CPC symbol, emerging focus area, type of applicant and leading industry / academic players (in terms of size of intellectual property portfolio) . It features a three-dimensional bubble analysis (based on patent citation count, publication year, extended geographical reach) . It also includes a patent benchmarking analysis and a detailed valuation analysis.

Chapter 9 presents a case study focused on novel cardiovascular therapeutics (such as gene therapy, next generation complements, oral proteins and peptides, regulatory t-cell (tregs) therapies and subcutaneous biologics) and novel cardiovascular-based services / solutions (such as biopharmaceutical contract research offerings, digital therapeutics and precision medicine software) , featuring a list of such players with details on their year of establishment, company size and location of headquarters. A detailed assessment of the overall market landscape of novel cardiovascular therapeutics is provided, based on the phase of development, route of administration, type of molecule, and mechanism of action. Further, an elaborate analysis of the overall market landscape of novel cardiovascular-based services / solutions is provided, based on several relevant parameters, such as types of services, purpose of software and end users.

Chapter 10 includes an in-depth analysis in order to estimate the current and future demand for cardiovascular drug eluting stents, based on several relevant parameters, such as type of drug eluted (sirolimus, paclitaxel, everolimus, zotarolimus and others), type of stent material (platinum chromium, cobalt chromium, stainless steel and others) and key geographical regions (North America, Europe, Asia, Middle East and North Africa, Latin America, and Rest of the World) for the period 2022-2035. Kindly note that the input parameters considered for this analysis include the number of patients suffering from cardiovascular disorders that can be treated using drug eluting stents and the average price of such stents across various geographies.

Chapter 11 features a comprehensive market forecast analysis, highlighting the likely growth of the cardiovascular drug eluting stents market, for the period 2022-2035. Additionally, the report features the likely distribution of the current and forecasted opportunity across various segments, such as type of drug eluted (sirolimus, paclitaxel, everolimus, zotarolimus and others), type of stent material (platinum chromium, cobalt chromium, stainless steel and others) and key geographical regions (North America, Europe, Asia, Middle East and North Africa, Latin America, and Rest of the World) .

Chapter 12 summarizes the overall report, wherein all the key facts and figures have been mentioned. Further, the chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the cardiovascular drug eluting stents market.

Chapter 13 is a collection of interview transcripts of discussions held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with several stakeholders.

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 15 is an appendix, which contains the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1 Chapter Overview
  • 3.2. Overview of Cardiovascular Drug Delivery Devices
    • 3.2.1. Types of Cardiovascular Drug Delivery Devices
      • 3.2.1.1. Drug Eluting Stents (DES)
      • 3.2.1.2. Drug Eluting Balloons (DEB)
  • 3.3. Key Indications Targeted by Cardiovascular Drug Delivery Devices
    • 3.3.1. Atherosclerosis
    • 3.3.2. Heart Failure
    • 3.3.3. In-Stent Restenosis
  • 3.4. Potential Risks Associated with Drug Eluting Stents and Balloons
  • 3.5. Recent Advancements Related to Cardiovascular Drug Delivery Devices
  • 3.6. Concluding Remarks

4. MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Cardiovascular Drug Eluting Stents: Overall Market Landscape
    • 4.2.1. Analysis by Type of Drug Eluted
    • 4.2.2. Analysis by Stent Material
    • 4.2.3. Analysis by Maximum Post Dilatation Limit
    • 4.2.4. Analysis by Maximum and Minimum Stent Length
    • 4.2.5. Analysis by Maximum and Minimum Stent Diameter
    • 4.2.6. Analysis by Maximum Nominal Pressure
    • 4.2.7. Analysis by Maximum Rated Burst Pressure
    • 4.2.8. Analysis by Administered Drug Concentration
    • 4.2.9. Analysis by Minimum Strut Thickness
  • 4.3. Cardiovascular Drug Eluting Stents: Developers Landscape
    • 4.3.1. Analysis by Year of Establishment
    • 4.3.2. Analysis by Company Size
    • 4.3.3. Analysis by Location of Headquarters
    • 4.3.4. Leading Players: Analysis by Number of Products

5. KEY INSIGHTS

  • 5.1. Chapter Overview
  • 5.2. Analysis by Eluted Drug and Administered Drug Concentration (Heat Map)
  • 5.3. Analysis by Eluted Drug and Stent Material (Stacked Bar Chart)
  • 5.4. Analysis by Maximum Stent Length and Maximum Stent Diameter (Tree Map)
  • 5.5. Analysis by Year of Establishment, Company Size, Number of Products Offered and Region (4D Bubble Chart)
  • 5.6. Analysis by Company Size, Region, Number of Products Offered, Maximum Stent Length and Maximum Stent Diameter (Grid Representation)

6. COMPANY COMPETITIVENESS

  • 6.1. Chapter Overview
  • 6.2. Key Assumptions and Parameters
  • 6.3. Methodology
    • 6.3.1. Company Competitiveness Analysis: Small Companies
    • 6.3.2. Company Competitiveness Analysis: Mid-sized Companies
    • 6.3.3. Company Competitiveness Analysis: Large Companies
    • 6.3.4. Company Competitiveness Analysis: Very Large Companies

7. COMPANY PROFILES

  • 7.1. Chapter Overview
  • 7.2. Alvimedica
    • 7.2.1. Company Overview
    • 7.2.2. Cardiovascular Drug Delivery Device Portfolio
    • 7.2.3. Recent Developments and Future Outlook
  • 7.3. B. Braun
    • 7.3.1. Company Overview
    • 7.3.2. Cardiovascular Drug Delivery Device Portfolio
    • 7.3.3. Recent Developments and Future Outlook
  • 7.4. Boston Scientific
    • 7.4.1. Company Overview
    • 7.4.2. Cardiovascular Drug Delivery Device Portfolio
    • 7.4.3. Recent Developments and Future Outlook
  • 7.5 Cook Medical
    • 7.5.1. Company Overview
    • 7.5.2. Cardiovascular Drug Delivery Device Portfolio
    • 7.5.3. Recent Developments and Future Outlook
  • 7.6. Endocor
    • 7.6.1. Company Overview
    • 7.6.2. Cardiovascular Drug Delivery Device Portfolio
    • 7.6.3. Recent Developments and Future Outlook
  • 7.7. Eurocor
    • 7.7.1. Company Overview
    • 7.7.2. Cardiovascular Drug Delivery Device Portfolio
    • 7.7.3. Recent Developments and Future Outlook
  • 7.8. iVascular
    • 7.8.1. Company Overview
    • 7.8.2. Cardiovascular Drug Delivery Device Portfolio
    • 7.8.3. Recent Developments and Future Outlook
  • 7.9. Lepu Medical
    • 7.9.1. Company Overview
    • 7.9.2. Cardiovascular Drug Delivery Device Portfolio
    • 7.9.3. Recent Developments and Future Outlook
  • 7.10. Medinol
    • 7.10.1. Company Overview
    • 7.10.2. Cardiovascular Drug Delivery Device Portfolio
    • 7.10.3. Recent Developments and Future Outlook
  • 7.11. Medtronic
    • 7.11.1. Company Overview
    • 7.11.2. Cardiovascular Drug Delivery Device Portfolio
    • 7.11.3. Recent Developments and Future Outlook
  • 7.12. Meril
    • 7.12.1. Company Overview
    • 7.12.2. Cardiovascular Drug Delivery Device Portfolio
    • 7.12.3. Recent Developments and Future Outlook
  • 7.13. Relisys Medical Devices
    • 7.13.1. Company Overview
    • 7.13.2. Cardiovascular Drug Delivery Device Portfolio
    • 7.13.3. Recent Developments and Future Outlook
  • 7.14. Sahajanand Medical Technologies
    • 7.14.1. Company Overview
    • 7.14.2. Cardiovascular Drug Delivery Device Portfolio
    • 7.14.3. Recent Developments and Future Outlook
  • 7.15. Sinomed
    • 7.15.1. Company Overview
    • 7.15.2. Cardiovascular Drug Delivery Device Portfolio
    • 7.15.3. Recent Developments and Future Outlook
  • 7.16. Vascular Concepts
    • 7.16.1. Company Overview
    • 7.16.2. Cardiovascular Drug Delivery Device Portfolio
    • 7.16.3. Recent Developments and Future Outlook

8. PATENT ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Scope and Methodology
  • 8.3. Cardiovascular Drug Eluting Stents: Patent Analysis
    • 8.3.1. Analysis by Type of Patent
    • 8.3.2. Analysis by Publication Year
    • 8.3.3. Analysis by Year of Granted Patents
    • 8.3.4. Analysis by Year of Filed Patent Applications
    • 8.3.5. Analysis by Issuing Authority
    • 8.3.6. Analysis by Patent Focus
    • 8.3.7. Analysis by Patent Age
    • 8.3.8. Analysis by CPC Symbols
    • 8.3.9. Leading Players: Analysis by Number of Patents
  • 8.4. Cardiovascular Drug Eluting Stents: Patent Benchmarking Analysis
    • 8.4.1. Analysis by Patent Characteristics
    • 8.4.2. Analysis by Geography
  • 8.5. Cardiovascular Drug Eluting Stents: Patent Valuation Analysis

9. CASE STUDY: NOVEL CARDIOVASCULAR THERAPEUTICS AND SERVICES / SOLUTIONS

  • 9.1. Chapter Overview
  • 9.2. Novel Cardiovascular Therapeutics
    • 9.2.1. Gene Therapy
    • 9.2.2. Next Generation Complement Therapeutics
    • 9.2.3. Oral Proteins and Peptides Therapies
    • 9.2.4. Regulatory T-Cell Therapies (Tregs) Therapies
    • 9.2.5. Subcutaneous Biologics
  • 9.3. Novel Cardiovascular-based Services / Solutions
    • 9.3.1. Biopharmaceutical Contract Research Offerings
    • 9.3.2. Digital Therapeutics Services
    • 9.3.3. Precision Medicine Software
    • 9.3.4. Virtual Clinical Trial Services

10. DEMAND ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Key Assumptions and Methodology
  • 10.3. Global Demand for Cardiovascular Drug Eluting Stents
    • 10.3.1. Analysis by Type of Drug Eluted
      • 10.3.1.1. Global Demand for Sirolimus Eluting Stents
      • 10.3.1.2. Global Demand for Paclitaxel Eluting Stents
      • 10.3.1.3. Global Demand for Everolimus Eluting Stents
      • 10.3.1.4. Global Demand for Zotarolimus Eluting Stents
      • 10.3.1.5. Global Demand for Other Drugs Eluting Stents
    • 10.3.2. Analysis by Stent Material
      • 10.3.2.1. Global Demand for Platinum Chromium Stents
      • 10.3.2.2. Global Demand for Cobalt Alloy Stents
      • 10.3.2.3. Global Demand for Stainless Steel Stents
      • 10.3.2.4. Global Demand for Other Stents
    • 10.3.3. Analysis by Geography
      • 10.3.3.1. Demand for Cardiovascular Drug Eluting Stents in North America
        • 10.3.3.1.1. Demand for Cardiovascular Drug Eluting Stents in the US
        • 10.3.3.1.2. Demand for Cardiovascular Drug Eluting Stents in Canada
      • 10.3.3.2. Demand for Cardiovascular Drug Eluting Stents in Europe
        • 10.3.3.2.1. Demand for Cardiovascular Drug Eluting Stents in France
        • 10.3.3.2.2. Demand for Cardiovascular Drug Eluting Stents in Germany
        • 10.3.3.2.3. Demand for Cardiovascular Drug Eluting Stents in Italy
        • 10.3.3.2.4. Demand for Cardiovascular Drug Eluting Stents in the Netherlands
        • 10.3.3.2.5. Demand for Cardiovascular Drug Eluting Stents in Spain
        • 10.3.3.2.6. Demand for Cardiovascular Drug Eluting Stents in the UK
      • 10.3.3.3. Demand for Cardiovascular Drug Eluting Stents in Asia
        • 10.3.3.3.1. Demand for Cardiovascular Drug Eluting Stents in China
        • 10.3.3.3.2. Demand for Cardiovascular Drug Eluting Stents in India
        • 10.3.3.3.3. Demand for Cardiovascular Drug Eluting Stents in Japan
        • 10.3.3.3.4. Demand for Cardiovascular Drug Eluting Stents in South Korea
      • 10.3.3.4. Demand for Cardiovascular Drug Eluting Stents in Middle East and North Africa
        • 10.3.3.4.1. Demand for Cardiovascular Drug Eluting Stents in Israel
        • 10.3.3.4.2. Demand for Cardiovascular Drug Eluting Stents in Turkey
      • 10.3.3.5. Demand for Cardiovascular Drug Eluting Stents in Latin America
        • 10.3.3.5.1. Demand for Cardiovascular Drug Eluting Stents in Brazil
      • 10.3.3.6. Demand for Cardiovascular Drug Eluting Stents in Rest of the World
        • 10.3.3.6.1. Demand for Cardiovascular Drug Eluting Stents in Australia
        • 10.3.3.6.2. Demand for Cardiovascular Drug Eluting Stents in New Zealand

11. MARKET FORECAST

  • 11.1. Chapter Overview
  • 11.2. Key Assumptions and Methodology
  • 11.3. Global Cardiovascular Drug Eluting Stents Market, 2022-2035
    • 11.3.1. Analysis by Type of Drug Eluted
      • 11.3.1.1. Global Sirolimus Eluting Stents Market
      • 11.3.1.2. Global Paclitaxel Eluting Stents Market
      • 11.3.1.3. Global Everolimus Eluting Stents Market
      • 11.3.1.4. Global Zotarolimus Eluting Stents Market
      • 11.3.1.5. Global Other Drugs Eluting Stents Market
    • 11.3.2. Analysis by Stent Material
      • 11.3.2.1. Global Platinum Chromium Stents Market
      • 11.3.2.2. Global Cobalt Alloy Stents Market
      • 11.3.2.3. Global Stainless Steel Stents Market
      • 11.3.2.4. Global Other Stents Market
    • 11.3.3. Analysis by Geography
      • 11.3.3.1. Cardiovascular Drug Eluting Stents Market in North America
        • 11.3.3.1.1. Cardiovascular Drug Eluting Stents Market in the US
        • 11.3.3.1.2. Cardiovascular Drug Eluting Stents Market in Canada
      • 11.3.3.2. Cardiovascular Drug Eluting Stents Market in Europe
        • 11.3.3.2.1. Cardiovascular Drug Eluting Stents Market in France
        • 11.3.3.2.2. Cardiovascular Drug Eluting Stents Market in Germany
        • 11.3.3.2.3. Cardiovascular Drug Eluting Stents Market in Italy
        • 11.3.3.2.4. Cardiovascular Drug Eluting Stents Market in the Netherlands
        • 11.3.3.2.5. Cardiovascular Drug Eluting Stents Market in Spain
        • 11.3.3.2.6. Cardiovascular Drug Eluting Stents Market in the UK
      • 11.3.3.3. Cardiovascular Drug Eluting Stents Market in Asia
        • 11.3.3.3.1. Cardiovascular Drug Eluting Stents Market in China
        • 11.3.3.3.2. Cardiovascular Drug Eluting Stents Market in India
        • 11.3.3.3.3. Cardiovascular Drug Eluting Stents Market in Japan
        • 11.3.3.3.4. Cardiovascular Drug Eluting Stents Market in South Korea
      • 11.3.3.4. Cardiovascular Drug Eluting Stents Market in Middle East and North Africa
        • 11.3.3.4.1. Cardiovascular Drug Eluting Stents Market in Israel
        • 11.3.3.4.2. Cardiovascular Drug Eluting Stents Market in Turkey
      • 11.3.3.5. Cardiovascular Drug Eluting Stents Market in Latin America
        • 11.3.3.5.1. Cardiovascular Drug Eluting Stents Market in Brazil
      • 11.3.3.6. Cardiovascular Drug Eluting Stents Market in Rest of the World
        • 11.3.3.6.1. Cardiovascular Drug Eluting Stents Market in Australia
        • 11.3.3.6.2. Cardiovascular Drug Eluting Stents Market in New Zealand

12. CONCLUSION

13. EXECUTIVE INSIGHTS

  • 13.1. Chapter Overview
  • 13.2. Scitech Medical
    • 13.2.1. Company Snapshot
    • 13.2.2. Interview Transcript: Luciano Curado, Chief Technology Officer
  • 13.3. Translumina
    • 13.3.1. Company Snapshot
    • 13.3.2. Interview Transcript: Harish Rawat, Production Executive

14. APPENDIX I: TABULATED DATA

15. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

  • Figure 3.1 Key Indications Targeted by Cardiovascular Drug Delivery Devices
  • Figure 3.2 Recent Advancements Related to Cardiovascular Drug Delivery Devices Domain
  • Figure 3.3 Evolution of Interventional Cardiology Devices
  • Figure 4.1 Cardiovascular Drug Eluting Stents: Distribution by Type of Drug Eluted
  • Figure 4.2 Cardiovascular Drug Eluting Stents: Distribution by Stent Material
  • Figure 4.3 Cardiovascular Drug Eluting Stents: Distribution by Maximum Post Dilatation Limit
  • Figure 4.4 Cardiovascular Drug Eluting Stents: Distribution by Maximum Stent Length
  • Figure 4.5 Cardiovascular Drug Eluting Stents: Distribution by Minimum Stent Length
  • Figure 4.6 Cardiovascular Drug Eluting Stents: Distribution by Maximum Stent Diameter
  • Figure 4.7 Cardiovascular Drug Eluting Stents: Distribution by Minimum Stent Diameter
  • Figure 4.8 Cardiovascular Drug Eluting Stents: Distribution by Maximum Nominal Pressure
  • Figure 4.9 Cardiovascular Drug Eluting Stents: Distribution by Maximum Rated Burst Pressure
  • Figure 4.10 Cardiovascular Drug Eluting Stents: Distribution by Administered Drug Concentration
  • Figure 4.11 Cardiovascular Drug Eluting Stents: Distribution by Minimum Strut Thickness
  • Figure 4.12 Cardiovascular Drug Eluting Stents Developers: Distribution by Year of Establishment
  • Figure 4.13 Cardiovascular Drug Eluting Stents Developers: Distribution by Company Size
  • Figure 4.14 Cardiovascular Drug Eluting Stents Developers: Distribution by Location of Headquarters
  • Figure 4.15 Leading Players: Distribution by Number of Products
  • Figure 5.1 Key Insights: Distribution by Type of Drug Eluted and Administered Drug Concentration
  • Figure 5.2 Key Insights: Distribution by Type of Drug Eluted and Stent Material
  • Figure 5.3 Key Insights: Distribution by Maximum Stent Length and Maximum Stent Diameter
  • Figure 5.4 Key Insights: Distribution by Year of Establishment, Company Size, Number of Products Offered and Location of Headquarters
  • Figure 5.5 Key Insights: Distribution by Company Size, Number of Products Offered, Maximum Stent Length, Maximum Stent Diameter and Location of Headquarters
  • Figure 6.1 Company Competitiveness Analysis: Small Companies
  • Figure 6.2 Company Competitiveness Analysis: Mid-sized Companies
  • Figure 6.3 Company Competitiveness Analysis: Large Companies
  • Figure 6.4 Company Competitiveness Analysis: Very Large Companies
  • Figure 8.1 Patent Analysis: Distribution by Type of Patent
  • Figure 8.2 Patent Analysis: Cumulative Distribution by Publication Year, 2017-2022
  • Figure 8.3 Patent Analysis: Distribution of Granted Patents by Publication Year, 2017-2022
  • Figure 8.4 Patent Analysis: Distribution of Filed Patents by Publication Year, 2017-2022
  • Figure 8.5 Patent Analysis: Distribution by Issuing Authority
  • Figure 8.6 Patent Analysis: Distribution by Patent Focus
  • Figure 8.7 Patent Analysis: Distribution by Patent Age
  • Figure 8.8 Patent Analysis: Distribution by CPC Symbols
  • Figure 8.9 Leading Players: Distribution by Number of Patents
  • Figure 8.10 Patent Analysis: Patent Valuation
  • Figure 9.1 Novel Cardiovascular Therapeutic Developers: Distribution by Year of Establishment
  • Figure 9.2 Novel Cardiovascular Therapeutic Developers: Distribution by Company Size
  • Figure 9.3 Novel Cardiovascular Therapeutic Developers: Distribution by Location of Headquarters
  • Figure 9.4 Novel Cardiovascular Therapeutic: Distribution by Type of Therapy
  • Figure 9.5 Gene Therapy: Distribution by Phase of Development
  • Figure 9.6 Gene Therapy: Distribution by Route of Administration
  • Figure 9.7 Gene Therapy: Distribution by Type of Gene Delivery Method
  • Figure 9.8 Subcutaneous Biologics: Distribution by Phase of Development
  • Figure 9.9 Subcutaneous Biologics: Distribution by Type of Molecule
  • Figure 9.10 Subcutaneous Biologics: Distribution by Phase of Development and Type of Molecule
  • Figure 9.11 Subcutaneous Biologics: Distribution by Mechanism of Action
  • Figure 9.12 Novel Cardiovascular-based Services / Solutions Providers: Distribution by Year of Establishment
  • Figure 9.13 Novel Cardiovascular-based Services / Solutions Providers: Distribution by Company Size
  • Figure 9.14 Novel Cardiovascular-based Services / Solutions Providers: Distribution by Location of Headquarters
  • Figure 9.15 Novel Cardiovascular-based Services / Solutions: Distribution by Type of Service / Solution
  • Figure 10.1 Global Demand for Cardiovascular Drug Eluting Stents, 2022-2035 (Million Units)
  • Figure 10.2 Global Demand for Cardiovascular Drug Eluting Stents: Distribution by Type of Drug Eluted, 2022 and 2035
  • Figure 10.3 Global Demand for Sirolimus Eluting Stents, 2022-2035 (Million Units)
  • Figure 10.4 Global Demand for Paclitaxel Eluting Stents, 2022-2035 (Million Units)
  • Figure 10.5 Global Demand for Everolimus Eluting Stents, 2022-2035 (Million Units)
  • Figure 10.6 Global Demand for Zotarolimus Eluting Stents, 2022-2035 (Million Units)
  • Figure 10.7 Global Demand for Other Drug Eluting Stents, 2022-2035 (Million Units)
  • Figure 10.8 Global Demand for Cardiovascular Drug Eluting Stents: Distribution by Stent Material, 2022 and 2035
  • Figure 10.9 Global Demand for Platinum Chromium Stents, 2022-2035 (Million Units)
  • Figure 10.10 Global Demand for Cobalt Alloy Stents, 2022-2035 (Million Units)
  • Figure 10.11 Global Demand for Stainless Steel Stents, 2022-2035 (Million Units)
  • Figure 10.12 Global Demand for Other Stents, 2022-2035 (Million Units)
  • Figure 10.13 Global Demand for Cardiovascular Drug Eluting Stents: Distribution by Geography, 2022 and 2035
  • Figure 10.14 Demand for Cardiovascular Drug Eluting Stents in North America, 2022-2035 (Million Units)
  • Figure 10.15 Demand for Cardiovascular Drug Eluting Stents in the US, 2022-2035 (Million Units)
  • Figure 10.16 Demand for Cardiovascular Drug Eluting Stents in Canada, 2022-2035 (Million Units)
  • Figure 10.17 Demand for Cardiovascular Drug Eluting Stents in Europe, 2022-2035 (Million Units)
  • Figure 10.18 Demand for Cardiovascular Drug Eluting Stents in France, 2022-2035 (Million Units)
  • Figure 10.19 Demand for Cardiovascular Drug Eluting Stents in Germany, 2022-2035 (Million Units)
  • Figure 10.20 Demand for Cardiovascular Drug Eluting Stents in Italy, 2022-2035 (Million Units)
  • Figure 10.21 Demand for Cardiovascular Drug Eluting Stents in the Netherlands, 2022-2035 (Million Units)
  • Figure 10.22 Demand for Cardiovascular Drug Eluting Stents in Spain, 2022-2035 (Million Units)
  • Figure 10.23 Demand for Cardiovascular Drug Eluting Stents in the UK, 2022-2035 (Million Units)
  • Figure 10.24 Demand for Cardiovascular Drug Eluting Stents in Asia, 2022-2035 (Million Units)
  • Figure 10.25 Demand for Cardiovascular Drug Eluting Stents in China, 2022-2035 (Million Units)
  • Figure 10.26 Demand for Cardiovascular Drug Eluting Stents in India, 2022-2035 (Million Units)
  • Figure 10.27 Demand for Cardiovascular Drug Eluting Stents in Japan, 2022-2035 (Million Units)
  • Figure 10.28 Demand for Cardiovascular Drug Eluting Stents in South Korea, 2022-2035 (Million Units)
  • Figure 10.29 Demand for Cardiovascular Drug Eluting Stents in Middle East and North Africa, 2022-2035 (Million Units)
  • Figure 10.30 Demand for Cardiovascular Drug Eluting Stents in Israel, 2022-2035 (Million Units)
  • Figure 10.31 Demand for Cardiovascular Drug Eluting Stents in Turkey, 2022-2035 (Million Units)
  • Figure 10.32 Demand for Cardiovascular Drug Eluting Stents in Latin America, 2022-2035 (Million Units)
  • Figure 10.33 Demand for Cardiovascular Drug Eluting Stents in Brazil, 2022-2035 (Million Units)
  • Figure 10.34 Demand for Cardiovascular Drug Eluting Stents in Rest of the World, 2022-2035 (Million Units)
  • Figure 10.35 Demand for Cardiovascular Drug Eluting Stents in Australia, 2022-2035 (Million Units)
  • Figure 10.36 Demand for Cardiovascular Drug Eluting Stents in New Zealand, 2022-2035 (Million Units)
  • Figure 11.1 Global Cardiovascular Drug Eluting Stents Market, 2022-2035 (USD Million)
  • Figure 11.2 Global Cardiovascular Drug Eluting Stents Market: Distribution by Type of Drug Eluted, 2022 and 2035
  • Figure 11.3 Global Sirolimus Eluting Stents Market, 2022-2035 (USD Million)
  • Figure 11.4 Global Paclitaxel Eluting Stents Market, 2022-2035 (USD Million)
  • Figure 11.5 Global Everolimus Eluting Stents Market, 2022-2035 (USD Million)
  • Figure 11.6 Global Zotarolimus Eluting Stents Market, 2022-2035 (USD Million)
  • Figure 11.7 Global Other Drug Eluting Stents Market, 2022-2035 (USD Million)
  • Figure 11.8 Global Cardiovascular Drug Eluting Stents Market: Distribution by Stent Material, 2022 and 2035
  • Figure 11.9 Global Platinum Chromium Stents Market, 2022-2035 (USD Million)
  • Figure 11.10 Global Cobalt Alloy Stents Market, 2022-2035 (USD Million)
  • Figure 11.11 Global Stainless Steel Stents Market, 2022-2035 (USD Million)
  • Figure 11.12 Global Other Stents Market, 2022-2035 (USD Million)
  • Figure 11.13 Global Cardiovascular Drug Eluting Stents Market: Distribution by Geography, 2022 and 2035
  • Figure 11.14 Cardiovascular Drug Eluting Stents Market in North America, 2022-2035 (USD Million)
  • Figure 11.15 Cardiovascular Drug Eluting Stents Market in the US, 2022-2035 (USD Million)
  • Figure 11.16 Cardiovascular Drug Eluting Stents Market in Canada, 2022-2035 (USD Million)
  • Figure 11.17 Cardiovascular Drug Eluting Stents Market in Europe, 2022-2035 (USD Million)
  • Figure 11.18 Cardiovascular Drug Eluting Stents Market in France, 2022-2035 (USD Million)
  • Figure 11.19 Cardiovascular Drug Eluting Stents Market in Germany, 2022-2035 (USD Million)
  • Figure 11.20 Cardiovascular Drug Eluting Stents Market in Italy, 2022-2035 (USD Million)
  • Figure 11.21 Cardiovascular Drug Eluting Stents Market in the Netherlands, 2022-2035 (USD Million)
  • Figure 11.22 Cardiovascular Drug Eluting Stents Market in Spain, 2022-2035 (USD Million)
  • Figure 11.23 Cardiovascular Drug Eluting Stents Market in the UK, 2022-2035 (USD Million)
  • Figure 11.24 Cardiovascular Drug Eluting Stents Market in Asia, 2022-2035 (USD Million)
  • Figure 11.25 Cardiovascular Drug Eluting Stents Market in China, 2022-2035 (USD Million)
  • Figure 11.26 Cardiovascular Drug Eluting Stents Market in India, 2022-2035 (USD Million)
  • Figure 11.27 Cardiovascular Drug Eluting Stents Market in Japan, 2022-2035 (USD Million)
  • Figure 11.28 Cardiovascular Drug Eluting Stents Market in South Korea, 2022-2035 (USD Million)
  • Figure 11.29 Cardiovascular Drug Eluting Stents Market in Middle East and North Africa, 2022-2035 (USD Million)
  • Figure 11.30 Cardiovascular Drug Eluting Stents Market in Israel, 2022-2035 (USD Million)
  • Figure 11.31 Cardiovascular Drug Eluting Stents Market in Turkey, 2022-2035 (USD Million)
  • Figure 11.32 Cardiovascular Drug Eluting Stents Market in Latin America, 2022-2035 (USD Million)
  • Figure 11.33 Cardiovascular Drug Eluting Stents Market in Brazil, 2022-2035 (USD Million)
  • Figure 11.34 Cardiovascular Drug Eluting Stents Market in Rest of the World, 2022-2035 (USD Million)
  • Figure 11.35 Cardiovascular Drug Eluting Stents Market in Australia, 2022-2035 (USD Million)
  • Figure 11.36 Cardiovascular Drug Eluting Stents Market in New Zealand, 2022-2035 (USD Million)
  • Figure 12.1 Concluding Remarks: Current Market Landscape
  • Figure 12.2 Concluding Remarks: Patent Analysis
  • Figure 12.3 Concluding Remarks: Demand Analysis
  • Figure 12.4 Concluding Remarks: Market Forecast

List Of Tables

  • Table 4.1 Cardiovascular Drug Eluting Stents: Information on Type of Drug Eluted
  • Table 4.2 Cardiovascular Drug Eluting Stents: Information on Stent Material
  • Table 4.3 Cardiovascular Drug Eluting Stents: Information on Maximum Post Dilatation Limit
  • Table 4.4 Cardiovascular Drug Eluting Stents: Information on Maximum and Minimum Stent Length
  • Table 4.5 Cardiovascular Drug Eluting Stents: Information on Maximum and Minimum Stent Diameter
  • Table 4.6 Cardiovascular Drug Eluting Stents: Information on Maximum Nominal Pressure
  • Table 4.7 Cardiovascular Drug Eluting Stents: Information on Maximum Rated Burst Pressure
  • Table 4.8 Cardiovascular Drug Eluting Stents: Information on Administered Drug Concentration
  • Table 4.9 Cardiovascular Drug Eluting Stents: Information on Minimum Strut Thickness
  • Table 4.10 Cardiovascular Drug Eluting Stent Providers: Information on Year of Establishment, Company Size, Location of Headquarters, Region of Headquarters and Number of Products
  • Table 5.1 Company Competitiveness Analysis: List of Small Players
  • Table 5.2 Company Competitiveness Analysis: List of Mid-sized Players
  • Table 5.3 Company Competitiveness Analysis: List of Large Players
  • Table 5.4 Company Competitiveness Analysis: List of Very Large Players
  • Table 7.1 List of Companies Profiled
  • Table 7.2 Alvimedica: Company Overview
  • Table 7.3 Alvimedica: Cardiovascular Drug Delivery Device Portfolio
  • Table 7.3 Alvimedica: Recent Developments and Future Outlook
  • Table 7.4 B. Braun: Company Overview
  • Table 7.5 B. Braun: Cardiovascular Drug Delivery Device Portfolio
  • Table 7.6 B. Braun: Recent Developments and Future Outlook
  • Table 7.7 Boston Scientific: Company Overview
  • Table 7.8 Boston Scientific: Cardiovascular Drug Delivery Device Portfolio
  • Table 7.9 Boston Scientific: Recent Developments and Future Outlook
  • Table 7.10 Cook Medical: Company Overview
  • Table 7.11 Cook Medical: Cardiovascular Drug Delivery Device Portfolio
  • Table 7.12 Cook Medical: Recent Developments and Future Outlook
  • Table 7.13 Endocor: Company Overview
  • Table 7.14 Endocor: Cardiovascular Drug Delivery Device Portfolio
  • Table 7.15 Endocor: Recent Developments and Future Outlook
  • Table 7.16 Eurocor: Company Overview
  • Table 7.17 Eurocor: Cardiovascular Drug Delivery Device Portfolio
  • Table 7.18 Eurocor: Recent Developments and Future Outlook
  • Table 7.19 iVascular: Company Overview
  • Table 7.20 iVascular: Cardiovascular Drug Delivery Device Portfolio
  • Table 7.21 iVascular: Recent Developments and Future Outlook
  • Table 7.22 Lepu Medical: Company Overview
  • Table 7.23 Lepu Medical: Cardiovascular Drug Delivery Device Portfolio
  • Table 7.24 Lepu Medical: Recent Developments and Future Outlook
  • Table 7.25 Medinol: Company Overview
  • Table 7.26 Medinol: Cardiovascular Drug Delivery Device Portfolio
  • Table 7.27 Medinol: Recent Developments and Future Outlook
  • Table 7.28 Medtronic: Company Overview
  • Table 7.29 Medtronic: Cardiovascular Drug Delivery Device Portfolio
  • Table 7.30 Medtronic: Recent Developments and Future Outlook
  • Table 7.31 Meril: Company Overview
  • Table 7.32 Meril: Cardiovascular Drug Delivery Device Portfolio
  • Table 7.33 Meril: Recent Developments and Future Outlook
  • Table 7.34 Relisys Medical Devices: Company Overview
  • Table 7.35 Relisys Medical Devices: Cardiovascular Drug Delivery Device Portfolio
  • Table 7.36 Relisys Medical Devices: Recent Developments and Future Outlook
  • Table 7.37 Sahajanand Medical Technologies: Company Overview
  • Table 7.38 Sahajanand Medical Technologies: Cardiovascular Drug Delivery Device Portfolio
  • Table 7.39 Sahajanand Medical Technologies: Recent Developments and Future Outlook
  • Table 7.40 Sinomed: Company Overview
  • Table 7.41 Sinomed: Cardiovascular Drug Delivery Device Portfolio
  • Table 7.42 Sinomed: Recent Developments and Future Outlook
  • Table 7.43 Vascular Concepts: Company Overview
  • Table 7.44 Vascular Concepts: Cardiovascular Drug Delivery Device Portfolio
  • Table 7.45 Vascular Concepts: Recent Developments and Future Outlook
  • Table 8.1 Patent Analysis: CPC Symbols
  • Table 8.2 Patent Analysis: Most Popular CPC Symbols
  • Table 8.3 Patent Analysis: List of Top CPC Symbols
  • Table 8.4 Patent Analysis: Categorization based on Weighted Valuation Scores
  • Table 8.5 Patent Analysis: List of Relatively Higher Value Patents
  • Table 13.1 Scitech Medical: Company Snapshot
  • Table 13.2 Translumina: Company Snapshot
  • Table 14.1 Cardiovascular Drug Eluting Stents: Distribution by Type of Drug Eluted
  • Table 14.2 Cardiovascular Drug Eluting Stents: Distribution by Stent Material
  • Table 14.3 Cardiovascular Drug Eluting Stents: Distribution by Maximum Post Dilatation Limit
  • Table 14.4 Cardiovascular Drug Eluting Stents: Distribution by Maximum Stent Length
  • Table 14.5 Cardiovascular Drug Eluting Stents: Distribution by Minimum Stent Length
  • Table 14.6 Cardiovascular Drug Eluting Stents: Distribution by Maximum Stent Diameter
  • Table 14.7 Cardiovascular Drug Eluting Stents: Distribution by Minimum Stent Diameter
  • Table 14.8 Cardiovascular Drug Eluting Stents: Distribution by Maximum Nominal Pressure
  • Table 14.9 Cardiovascular Drug Eluting Stents: Distribution by Maximum Rated Burst Pressure
  • Table 14.10 Cardiovascular Drug Eluting Stents: Distribution by Administered Drug Concentration
  • Table 14.11 Cardiovascular Drug Eluting Stents: Distribution by Minimum Strut Thickness
  • Table 14.12 Cardiovascular Drug Eluting Stents Developers: Distribution by Year of Establishment
  • Table 14.13 Cardiovascular Drug Eluting Stents Developers: Distribution by Company Size
  • Table 14.14 Cardiovascular Drug Eluting Stents Developers: Distribution by Location of Headquarters
  • Table 14.15 Leading Players: Distribution by Number of Products
  • Table 14.16 Key Insights: Distribution by Type of Drug Eluted and Administered Drug Concentration
  • Table 14.17 Key Insights: Distribution by Type of Drug Eluted and Stent Material
  • Table 14.18 Key Insights: Distribution by Maximum Stent Length and Maximum Stent Diameter
  • Table 14.19 Key Insights: Distribution by Year of Establishment, Company Size, Number of Products Offered and Location of Headquarters
  • Table 14.20 Key Insights: Distribution by Company Size, Number of Products Offered, Maximum Stent Length, Maximum Stent Diameter and Location of Headquarters
  • Table 14.21 Patent Analysis: Distribution by Type of Patent
  • Table 14.22 Patent Analysis: Cumulative Distribution by Publication Year, 2017-2022
  • Table 14.23 Patent Analysis: Distribution of Granted Patents by Publication Year, 2017-2022
  • Table 14.24 Patent Analysis: Distribution of Filed Patents by Publication Year, 2017-2022
  • Table 14.25 Patent Analysis: Distribution by Issuing Authority
  • Table 14.26 Patent Analysis: Distribution by Patent Focus
  • Table 14.27 Patent Analysis: Distribution by Patent Age
  • Table 14.28 Patent Analysis: Distribution by CPC Symbols
  • Table 14.29 Leading Players: Distribution by Number of Patents
  • Table 14.30 Patent Analysis: Patent Valuation
  • Table 14.31 Novel Cardiovascular Therapeutic Developers: Distribution by Year of Establishment
  • Table 14.32 Novel Cardiovascular Therapeutic Developers: Distribution by Company Size
  • Table 14.33 Novel Cardiovascular Therapeutic Developers: Distribution by Location of Headquarters
  • Table 14.34 Novel Cardiovascular Therapeutic: Distribution by Type of Therapy
  • Table 14.35 Gene Therapy: Distribution by Phase of Development
  • Table 14.36 Gene Therapy: Distribution by Route of Administration
  • Table 14.37 Gene Therapy: Distribution by Type of Gene Delivery Method
  • Table 14.38 Subcutaneous Biologics: Distribution by Phase of Development
  • Table 14.39 Subcutaneous Biologics: Distribution by Type of Molecule
  • Table 14.40 Subcutaneous Biologics: Distribution by Phase of Development and Type of Molecule
  • Table 14.41 Subcutaneous Biologics: Distribution by Mechanism of Action
  • Table 14.42 Novel Cardiovascular-based Services / Solutions Providers: Distribution by Year of Establishment
  • Table 14.43 Novel Cardiovascular-based Services / Solutions Providers: Distribution by Company Size
  • Table 14.44 Novel Cardiovascular-based Services / Solutions Providers: Distribution by Location of Headquarters
  • Table 14.45 Novel Cardiovascular-based Services / Solutions: Distribution by Type of Service / Solution
  • Table 14.46 Global Demand for Cardiovascular Drug Eluting Stents, 2022-2035 (Million Units)
  • Table 14.47 Global Demand for Cardiovascular Drug Eluting Stents: Distribution by Type of Drug Eluted, 2022 and 2035
  • Table 14.48 Global Demand for Sirolimus Eluting Stents, 2022-2035 (Million Units)
  • Table 14.49 Global Demand for Paclitaxel Eluting Stents, 2022-2035 (Million Units)
  • Table 14.50 Global Demand for Everolimus Eluting Stents, 2022-2035 (Million Units)
  • Table 14.51 Global Demand for Zotarolimus Eluting Stents, 2022-2035 (Million Units)
  • Table 14.52 Global Demand for Other Drug Eluting Stents, 2022-2035 (Million Units)
  • Table 14.53 Global Demand for Cardiovascular Drug Eluting Stents: Distribution by Stent Material, 2022 and 2035
  • Table 14.54 Global Demand for Platinum Chromium Stents, 2022-2035 (Million Units)
  • Table 14.55 Global Demand for Cobalt Alloy Stents, 2022-2035 (Million Units)
  • Table 14.56 Global Demand for Stainless Steel Stents, 2022-2035 (Million Units)
  • Table 14.57 Global Demand for Other Stents, 2022-2035 (Million Units)
  • Table 14.58 Global Demand for Cardiovascular Drug Eluting Stents: Distribution by Geography, 2022 and 2035
  • Table 14.59 Demand for Cardiovascular Drug Eluting Stents in North America, 2022-2035 (Million Units)
  • Table 14.60 Demand for Cardiovascular Drug Eluting Stents in the US, 2022-2035 (Million Units)
  • Table 14.61 Demand for Cardiovascular Drug Eluting Stents in Canada, 2022-2035 (Million Units)
  • Table 14.62 Demand for Cardiovascular Drug Eluting Stents in Europe, 2022-2035 (Million Units)
  • Table 14.63 Demand for Cardiovascular Drug Eluting Stents in France, 2022-2035 (Million Units)
  • Table 14.64 Demand for Cardiovascular Drug Eluting Stents in Germany, 2022-2035 (Million Units)
  • Table 14.65 Demand for Cardiovascular Drug Eluting Stents in Italy, 2022-2035 (Million Units)
  • Table 14.66 Demand for Cardiovascular Drug Eluting Stents in the Netherlands, 2022-2035 (Million Units)
  • Table 14.67 Demand for Cardiovascular Drug Eluting Stents in Spain, 2022-2035 (Million Units)
  • Table 14.68 Demand for Cardiovascular Drug Eluting Stents in the UK, 2022-2035 (Million Units)
  • Table 14.69 Demand for Cardiovascular Drug Eluting Stents in Asia, 2022-2035 (Million Units)
  • Table 14.70 Demand for Cardiovascular Drug Eluting Stents in China, 2022-2035 (Million Units)
  • Table 14.71 Demand for Cardiovascular Drug Eluting Stents in India, 2022-2035 (Million Units)
  • Table 14.72 Demand for Cardiovascular Drug Eluting Stents in Japan, 2022-2035 (Million Units)
  • Table 14.73 Demand for Cardiovascular Drug Eluting Stents in South Korea, 2022-2035 (Million Units)
  • Table 14.74 Demand for Cardiovascular Drug Eluting Stents in Middle East and North Africa, 2022-2035 (Million Units)
  • Table 14.75 Demand for Cardiovascular Drug Eluting Stents in Israel, 2022-2035 (Million Units)
  • Table 14.76 Demand for Cardiovascular Drug Eluting Stents in Turkey, 2022-2035 (Million Units)
  • Table 14.77 Demand for Cardiovascular Drug Eluting Stents in Latin America, 2022-2035 (Million Units)
  • Table 14.78 Demand for Cardiovascular Drug Eluting Stents in Brazil, 2022-2035 (Million Units)
  • Table 14.79 Demand for Cardiovascular Drug Eluting Stents in Rest of the World, 2022-2035 (Million Units)
  • Table 14.80 Demand for Cardiovascular Drug Eluting Stents in Australia, 2022-2035 (Million Units)
  • Table 14.81 Demand for Cardiovascular Drug Eluting Stents in New Zealand, 2022-2035 (Million Units)
  • Table 14.82 Global Cardiovascular Drug Eluting Stents Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 14.83 Global Cardiovascular Drug Eluting Stents Market: Distribution by Type of Drug Eluted, 2022 and 2035
  • Table 14.84 Global Sirolimus Eluting Stents Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 14.85 Global Paclitaxel Eluting Stents Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 14.86 Global Everolimus Eluting Stents Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 14.87 Global Zotarolimus Eluting Stents Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 14.88 Global Other Drug Eluting Stents Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 14.89 Global Cardiovascular Drug Eluting Stents Market: Distribution by Stent Material, 2022 and 2035
  • Table 14.90 Global Platinum Chromium Stents Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 14.91 Global Cobalt Alloy Stents Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 14.92 Global Stainless Steel Stents Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 14.93 Global Other Stents Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 14.94 Global Cardiovascular Drug Eluting Stents Market: Distribution by Geography, 2022 and 2035
  • Table 14.95 Cardiovascular Drug Eluting Stents Market in North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 14.96 Cardiovascular Drug Eluting Stents Market in the US, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 14.97 Cardiovascular Drug Eluting Stents Market in Canada, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 14.98 Cardiovascular Drug Eluting Stents Market in Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 14.99 Cardiovascular Drug Eluting Stents Market in France, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 14.100 Cardiovascular Drug Eluting Stents Market in Germany, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 14.101 Cardiovascular Drug Eluting Stents Market in Italy, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 14.102 Cardiovascular Drug Eluting Stents Market in the Netherlands, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 14.103 Cardiovascular Drug Eluting Stents Market in Spain, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 14.104 Cardiovascular Drug Eluting Stents Market in the UK, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 14.105 Cardiovascular Drug Eluting Stents Market in Asia, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 14.106 Cardiovascular Drug Eluting Stents Market in China, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 14.107 Cardiovascular Drug Eluting Stents Market in India, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 14.108 Cardiovascular Drug Eluting Stents Market in Japan, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 14.109 Cardiovascular Drug Eluting Stents Market in South Korea, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 14.110 Cardiovascular Drug Eluting Stents Market in Middle East and North Africa, 2022-2035 (USD Million)
  • Table 14.111 Cardiovascular Drug Eluting Stents Market in Israel, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 14.112 Cardiovascular Drug Eluting Stents Market in Turkey, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 14.113 Cardiovascular Drug Eluting Stents Market in Latin America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 14.114 Cardiovascular Drug Eluting Stents Market in Brazil, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 14.115 Cardiovascular Drug Eluting Stents Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 14.116 Cardiovascular Drug Eluting Stents Market in Australia, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
  • Table 14.117 Cardiovascular Drug Eluting Stents Market in New Zealand, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)

List Of Companies

The following companies and organizations have been mentioned in the report:

  • 1. AaviGen
  • 2. Abbott
  • 3. Abiogenesis Clinpharm
  • 4. Acceleron (Acquired by Merck)
  • 5. Accura Medizintechnik
  • 6. Aesculap (Acquired by B. Braun)
  • 7. Aesculape CRO
  • 8. Alexion
  • 9. Alnylam
  • 10. Alvimedica
  • 11. Ambulero
  • 12. American Heart Association
  • 13. amg International
  • 14. Amgen
  • 15. Amsino
  • 16. Anaeropharma Science
  • 17. AnGes
  • 18. Angionetics
  • 19. Anlong Bio
  • 20. Asklepios BioPharmaceutical
  • 21. Astellas
  • 22. AstraZeneca
  • 23. B. Braun
  • 24. Balton
  • 25. BioMarin
  • 26. Biosensors International
  • 27. BIOTRONIK
  • 28. Boston Scientific
  • 29. Breakthrough Genomics
  • 30. Bristol Myers Squibb
  • 31. California Institute of Technology
  • 32. Cambridge University Hospitals NHS Foundation Trust
  • 33. Cardionovum
  • 34. CiVi Biopharma
  • 35. Cohesic
  • 36. Consip
  • 37. Cook Medical
  • 38. Corvidia Therapeutics
  • 39. DiNAQOR
  • 40. Dyno Therapeutics
  • 41. Eli Lilly
  • 42. Elixir Medical
  • 43. ENDOCOR
  • 44. Eucatech
  • 45. Eurocor
  • 46. Excelya
  • 47. Genedata
  • 48. Genelife Clinical Research
  • 49. Genoss
  • 50. Helixmith
  • 51. HP
  • 52. Huapont Life Sciences
  • 53. Human Longevity
  • 54. Human Stem Cells Institute
  • 55. Hygea Precision Medicine
  • 56. Infraredx
  • 57. Innovent Biologics
  • 58. InSitu Technologies
  • 59. Integer
  • 60. Ionis Pharmaceuticals
  • 61. iVascular
  • 62. Jiangsu Hengrui Medicine
  • 63. Johnson & Johnson
  • 64. Lepu Medical
  • 65. LEXEO Therapeutics
  • 66. Liaoning Yinyi Biological Technology
  • 67. LIB Therapeutics
  • 68. LifeOmic
  • 69. Medinol
  • 70. Medipredict
  • 71. Medtronic
  • 72. Meril
  • 73. Metabolon
  • 74. MicroPort
  • 75. Minvasys
  • 76. Mitsubishi Tanabe Pharma
  • 77. Multimedics
  • 78. Nuevocor
  • 79. Novartis
  • 80. N-ovative Health Technologies
  • 81. Numed Technologies
  • 82. Oracle
  • 83. Perceiv AI
  • 84. Pharming
  • 85. PhaseBio
  • 86. Precigen
  • 87. QAscent Research Solutions
  • 88. QualiMed
  • 89. Regeneron
  • 90. Relisys Medical Devices
  • 91. Renalytix
  • 92. Renova Therapeutics
  • 93. REVA Medical
  • 94. REYON Pharmaceuticals
  • 95. Rontis
  • 96. R-Pharm
  • 97. S3V Vascular Technologies
  • 98. Sahajanand Laser Technology
  • 99. Sahajanand Medical Technologies
  • 100. SalioGen Therapeutics
  • 101. Sarepta Therapeutics
  • 102. SCITECH Medical
  • 103. Siguler Guff
  • 104. SINOMED
  • 105. Skyline Therapeutics
  • 106. SOPHiA GENETICS
  • 107. Steel Partners
  • 108. Strand Life Sciences
  • 109. StrideBio
  • 110. Tenaya Therapeutics
  • 111. Terumo
  • 112. Translumina
  • 113. uniQure
  • 114. University of Florida
  • 115. USM Healthcare
  • 116. Vascular Concepts (Acquired by Sahajanand Medical Technologies)
  • 117. VBL Therapeutics
  • 118. Verily
  • 119. XBiotech
  • 120. Xcene Research
  • 121. XyloCor Therapeutics
  • 122. Zarek Distribuidora De Produtos Hospitalares (Acquired by Sahajanand Medical Technologies)
  • 123. Zensun